Common decision limits - The need for harmonised immunoassays

Clinica Chimica Acta

Volumn 432, Issue , 2014, Pages 122-126

  Sturgeon, Catharine M ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Clinical outcome; Decision limits; Method related differences; Standardisation

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; FOLLITROPIN; GROWTH HORMONE; HEMOGLOBIN A1C; MUELLERIAN INHIBITING FACTOR; PARATHYROID HORMONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; THYROTROPIN; TROPONIN I; TROPONIN T;

ANALYTICAL PARAMETERS; ANTIBODY SPECIFICITY; ARTICLE; BETWEEN METHOD AGREEMENT; BLOOD SAMPLING; CALIBRATION; CLINICAL DECISION MAKING; COMMON DECISION LIMIT; COMPUTER SIMULATION; HUMAN; IMMUNOASSAY; LABORATORY TEST; MEASUREMENT ACCURACY; MEDICAL AUDIT; MEDICAL PROCEDURES; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REFERENCE MEASUREMENT PROCEDURE; STANDARDIZATION; CLINICAL CHEMISTRY; INTERNATIONAL COOPERATION; LIMIT OF DETECTION; PROCEDURES; STANDARD; STANDARDS;

CALIBRATION; CLINICAL CHEMISTRY TESTS; HUMANS; IMMUNOASSAY; INTERNATIONALITY; LIMIT OF DETECTION; REFERENCE STANDARDS;

EID: 84901600708     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.11.023     Document Type: Article

References (27)

1. Gray J.A. The shift to personalised and population medicine. Lancet 2013, 382:200-201.
2. Klee G.G. Establishment of outcome-related analytic performance goals. Clin Chem 2010, 56:714-722.
3. Madsen J.S., Nybo M., Magid E., et al. More studies on outcomes using biochemical diagnostic tests are needed: findings from the Danish Society of Clinical Biochemistry. Clin Chem 2008, 54:1254-1256.
4. Roddam A.W., Price C.P., Allen N.E., Ward A.M. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 2004, 50:1012-1016.
5. Melia J., Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001, 85:656-657.
6. Sturgeon C.M., Ellis A.R. Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems. Clin Chim Acta 2007, 381:85-92.
7. Almond A., Ellis A.R., Walker S.W. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012, 49:63-67.
8. Steddon S., Sharples E. Renal Association Clinical Practice Guideline in mineral and bone disorders in CKD. Nephron Clin Pract 2011, 118(Suppl. 1):c145-c152.
9. Miller W.G., Jones G.R., Horowitz G.L., Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem 2011, 57:1670-1680.
10. Miller W.G., Myers G.L., Rej R. Why commutability matters. Clin Chem 2006, 52:553-554.
11. Miller W.G., Myers G.L., Gantzer M.L., et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 2011, 57:1108-1117.
12. Thienpont L.M. Accuracy in clinical chemistry - who will kiss Sleeping Beauty awake?. Clin Chem Lab Med 2008, 46:1220-1222.
13. John W.G. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med 2012, 29:1350-1357.
14. NICE Clinical Guideline 122 The recognition and initial management of ovarian cancer 2011, [See http://guidance.nice.org.uk/CG/Wave17/22 (Last checked 30th August 2013)].
15. NICE Clinical Guideline TA64. Growth hormone deficiency (adults) - human growth hormone (TA64). See (Last checked 30th August 2013). http://guidance.nice.org.uk/TA64.
16. Little R.R., Rohlfing C.L., Sacks D.B. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011, 57:205-214.
17. Sturgeon C.M., Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem 2011, 48:418-432.
18. Little R.R., Roberts W.L. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol 2009, 3:446-451.
19. DQASS risk calculation software requirements for Down's syndrome screening 2013, [http://fetalanomaly.screening.nhs.uk/dqasspublications [Last accessed 30th August 2013]].
20. Thienpont L.M., Van Uytfanghe K., Beastall G., et al. Report of the IFCC working group for standardization of thyroid function tests; part 1: thyroid-stimulating hormone. Clin Chem 2010, 56:902-911.
21. Van Houcke S.K., Thienpont L.M. Good samples make good assays& - the problem of sourcing clinical samples for a standardization project. Clin Chem Lab Med 2013, 51:967-972.
22. Bristow A., Berger P., Bidart J.M., et al. Establishment, value assignment, and characterization of new WHO reference reagents for six molecular forms of human chorionic gonadotropin. Clin Chem 2005, 51:177-182.
23. Sturgeon C.M., Berger P., Bidart J.M., et al. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem 2009, 55:1484-1491.
24. Berger P., Sturgeon C., Bidart J.M., et al. The ISOBM TD-7 workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives. Tumour Biol 2002, 23:1-38.
25. Rosner W., Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 2010, 95:4542-4548.
26. Sturgeon C.M., Sprague S.M., Metcalfe W. Variation in parathyroid hormone immunoassay results-a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011, 26:3440-3445.
27. Hanon E., Sturgeon C.M., Lamb E.J. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med 2013, 51(10):1925-1941.